Kenneth Kwok
About
Kenneth Kwok is a scholar working on Rheumatology, Hematology and Genetics.
According to data from OpenAlex, Kenneth Kwok has authored 60 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Rheumatology, 20 papers in Hematology and 15 papers in Genetics. Recurrent topics in Kenneth Kwok's work include Rheumatoid Arthritis Research and Therapies (35 papers), Autoimmune and Inflammatory Disorders Research (20 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Kenneth Kwok is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (35 papers), Autoimmune and Inflammatory Disorders Research (20 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Kenneth Kwok collaborates with scholars based in United States, Germany and United Kingdom. Kenneth Kwok's co-authors include Lisy Wang, Ryan DeMasi, Stanley Cohen, Koshika Soma, Christina Charles‐Schoeman, J. Wollenhaupt, Richard J. Riese, Jeffrey R. Curtis, Peter Nash and Jamie Geier and has published in prestigious journals such as Gastroenterology, Annals of the Rheumatic Diseases and The American Journal of Gastroenterology.
In The Last Decade
Kenneth Kwok
56 papers receiving 1.6k citations
Hit Papers
Peers
Kenneth Kwok
Jonathan S. Coblyn United States
Serena Bugatti Italy
Elena Massarotti United States
J O'donnell New Zealand
Taeko Ishii Japan
Marcel D. Posthumus Netherlands
Toshihiko Hidaka Japan
Jerzy Świerkot Poland
J. R. Kalden Germany
A. Gerards Netherlands
Citations per year, relative to Kenneth Kwok Kenneth Kwok (= 1×)
peers
Jonathan S. Coblyn
Countries citing papers authored by Kenneth Kwok
Since
Specialization
Citations
This map shows the geographic impact of Kenneth Kwok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Kwok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Kwok more than expected).
Fields of papers citing papers by Kenneth Kwok
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kenneth Kwok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Kwok. The network helps show where Kenneth Kwok may publish in the future.
Co-authorship network of co-authors of Kenneth Kwok
This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth Kwok. A scholar is included among the top collaborators of Kenneth Kwok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth Kwok. Kenneth Kwok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Baraliakos, Xenofon, et al.. (2024). Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies. Rheumatology and Therapy. 11(3). 583–597.
2.
Buch, Maya H, Deepak L. Bhatt, Christina Charles‐Schoeman, et al.. (2024). Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD Open. 10(2). e003912–e003912.
3.
Schreiber, Stefan, David T. Rubin, Siew C. Ng, et al.. (2023). Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme. Journal of Crohn s and Colitis. 17(11). 1761–1770.
4.
Burmester, Gerd R, Laura C. Coates, Stanley Cohen, et al.. (2023). Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Rheumatology and Therapy. 10(5). 1255–1276.
5.
Ciurea, Adrian, Oliver Distler, Kenneth Kwok, et al.. (2023). Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start. Arthritis Research & Therapy. 25(1). 185–185.
6.
Winthrop, Kevin, Arne Yndestad, Dan Henrohn, et al.. (2022). Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatology and Therapy. 10(2). 357–373.
7.
Müeller, Ruediger B., Hendrik Schulze‐Koops, Daniel E. Furst, et al.. (2022). Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). Clinical Rheumatology. 41(4). 1045–1055.
8.
Schreiber, Stefan, David T. Rubin, Siew C. Ng, et al.. (2022). S775 Major Cardiovascular Adverse Events by Baseline Cardiovascular Risk Stratification in Patients With Ulcerative Colitis Treated With Tofacitinib: Data From the OCTAVE Clinical Program. The American Journal of Gastroenterology. 117(10S). e551–e552.
9.
Winthrop, Kevin, Jeffrey R. Curtis, Kunihiro Yamaoka, et al.. (2021). Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatology and Therapy. 9(1). 243–263.
10.
Rubin, David T., Marla C. Dubinsky, Silvio Danese, et al.. (2020). Tu1866 EFFICACY AND SAFETY OF AN ADDITIONAL 8 WEEKS OF TOFACITINIB INDUCTION THERAPY: UPDATED RESULTS OF THE OCTAVE OPEN STUDY FOR TOFACITINIB 8-WEEK INDUCTION NON-RESPONDERS. Gastroenterology. 158(6). S–1194.
11.
Panaccione, Remo, John D. Isaacs, Lea Ann Chen, et al.. (2020). Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive Diseases and Sciences. 66(9). 3214–3215.
12.
Panaccione, Remo, John D. Isaacs, Lea Ann Chen, et al.. (2020). Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive Diseases and Sciences. 66(8). 2732–2743.
13.
Wollenhaupt, J., Jeffrey R. Curtis, Joel C. Silverfield, et al.. (2019). Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Research & Therapy. 21(1). 89–89.
14.
Strand, Vibeke, Arthur Kavanaugh, Alan Kivitz, et al.. (2018). Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. Rheumatology and Therapy. 5(2). 341–353.
15.
Heijde, D. van der, J. Wollenhaupt, Stanley Cohen, et al.. (2017). Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years. Arthritis & Rheumatism. 69.
16.
Schulze‐Koops, Hendrik, Vibeke Strand, Chudy I. Nduaka, et al.. (2016). Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Lara D. Veeken. 56(1). 46–57.
17.
Charles‐Schoeman, Christina, Pierre Wicker, Miguel Á. González‐Gay, et al.. (2016). Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Seminars in Arthritis and Rheumatism. 46(3). 261–271.
18.
Charles‐Schoeman, Christina, Gerd R Burmester, Peter Nash, et al.. (2015). Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases. 75(7). 1293–1301.
19.
Buys, Yvonne M., Rania Gaspo, & Kenneth Kwok. (2012). Referral source, symptoms, and severity at diagnosis of ocular hypertension or open-angle glaucoma in various practices. Canadian Journal of Ophthalmology. 47(3). 217–222.
20.
You, Peng, Kenneth Kwok, Pengfei Yang, et al.. (2005). Ascorbic acid inhibits ROS production, NF-?B activation and prevents ethanol-induced growth retardation and microencephaly. Neuropharmacology. 48(3). 426–434.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jonathan S. Coblyn Breakdown of academic impact, for papers by Serena Bugatti Breakdown of academic impact, for papers by Elena Massarotti Breakdown of academic impact, for papers by J O'donnell Breakdown of academic impact, for papers by Taeko Ishii Breakdown of academic impact, for papers by Marcel D. Posthumus Breakdown of academic impact, for papers by Toshihiko Hidaka Breakdown of academic impact, for papers by Jerzy Świerkot Breakdown of academic impact, for papers by J. R. Kalden Breakdown of academic impact, for papers by A. Gerards